^
Association details:
| Biomarker: | High MHC-II signature |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
Published date:
02/11/2022
Excerpt:
...we divided the patients into MHC-H and MHC-L groups according to the median level of the MHC-II signature score of all samples....The IC50 values of Cisplatin, Docetaxel, Sunitinib, and NU.7441 in the MHC-H group were significantly lower than those of the MHC-L group, and all of these values were significantly correlated with the MHC-II signature score all P < 0.001...Finally, we identified a significant increase in drug sensitivity to cisplatin, docetaxel, sunitinib and NU.7441 in the MHC-H group.
DOI:
https://doi.org/10.3389/fcell.2022.757137
